Bessemer Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Bessemer Group’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-73	Closed	-$1K	–	2109
2022 Q3	$1K	Hold	73	–	–	﹤0.01%	1983
2022 Q2	$1K	Hold	73	–	–	﹤0.01%	1829
2022 Q1	$2K	Hold	73	–	–	﹤0.01%	1733
2021 Q4	$2K	Hold	73	–	–	﹤0.01%	1775
2021 Q3	$3K	Hold	73	–	–	﹤0.01%	1584
2021 Q2	$3K	Hold	73	–	–	﹤0.01%	1492
2021 Q1	$2K	Hold	73	–	–	﹤0.01%	1462
2020 Q4	$3K	Hold	73	–	–	﹤0.01%	1422
2020 Q3	$2K	Hold	73	–	–	﹤0.01%	1284
2020 Q2	$1K	Hold	73	–	–	﹤0.01%	1676
2020 Q1	$1K	Hold	73	–	–	﹤0.01%	1587
2019 Q4	$2K	Hold	73	–	–	﹤0.01%	1561
2019 Q3	$1K	Hold	73	–	–	﹤0.01%	1676
2019 Q2	$2K	Hold	73	–	–	﹤0.01%	1591
2019 Q1	$2K	Hold	73	–	–	﹤0.01%	1685
2018 Q4	$2K	Buy	+73	New	+$2.06K	﹤0.01%	1880

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bessemer Group's RIGL Position: Q4 2022 in Review

Bessemer Group sold out of Rigel Pharmaceuticals (RIGL) in Q4 2022, closing a stake of 73 shares — an estimated $1K sold.

Bessemer Group first reported a position in RIGL in Q4 2018 and held it in 16 quarters. The position peaked at $3K in Q3 2021. 118 funds tracked by Wall St. Rank hold RIGL as of Q4 2022.

Bessemer Group reported no remaining Rigel Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Bessemer Group sold 73 Rigel Pharmaceuticals shares in Q4 2022, an estimated $1K.
Bessemer Group first reported a position in Rigel Pharmaceuticals in Q4 2018 and held it in 16 quarters.
Bessemer Group's Rigel Pharmaceuticals position peaked at $3K in Q3 2021.
118 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2022.

Based on Bessemer Group's 13F filing for Q4 2022, filed 13 Feb 2023.